The Power of VOC Prevention
ADAKVEO® (crizanlizumab) was developed for SCD and is the first and only once-monthly treatment for the prevention of vaso-occlusive crises1
VOCs are the clinical hallmark of SCD.2 Learn why preventing VOCs is important for your patients.
ADAKVEO was proven to prevent VOCs across all patient types in the SUSTAIN clinical trial.1
Learn about the scientific discoveries that led to the development of ADAKVEO.
ADAKVEO is the first and only approved targeted monoclonal antibody that works by inhibiting P-selectin-mediated multicellular adhesion in SCD—thereby preventing vaso-occlusion.1,3